1442452-05-2

Basic information

• Product Name: 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-N-methoxy-4,N-dimethyl-benzamide
• Synonyms: 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-N-methoxy-4,N-dimethyl-benzamide
• CAS NO: 1442452-05-2
• Molecular Weight: 445.878
• Mol File: 1442452-05-2.mol

Chemical Properties

• CAS DataBase Reference: 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-N-methoxy-4,N-dimethyl-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-N-methoxy-4,N-dimethyl-benzamide(1442452-05-2)
• EPA Substance Registry System: 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-N-methoxy-4,N-dimethyl-benzamide(1442452-05-2)

Safety Data

• Hazardous Substances Data: 1442452-05-2(Hazardous Substances Data)

Upstream product

• 773103-91-6 3-[1-(2-methoxycarbonyl-acetylamino)-ethylideneamino]-4-methyl-benzoic acid methyl ester 
• 773103-89-2 3-acetimidoylamino-4-methyl-benzoic acid methyl ester 
• 1442451-95-7 3-[5-chloro-4-(4-methoxy-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-4-methyl-benzoic acid methyl ester 
• 1442451-94-6 3-[4-(4-methoxy-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-4-methyl-benzoic acid methyl ester 
• 1442451-93-5 3-(4-hydroxy-2-methyl-6-oxo-6H-pyrimidin-1-yl)-4-methyl-benzoic acid methyl ester 
• 1442452-04-1 3-[5-chloro-4-(4-fluoro-benzyloxy)-2-methyl-6-oxo-6H-pyrimidin-1-yl]-4-methyl-benzoic acid methyl ester 
• 16645-06-0 N,N-dimethylhydroxylamine hydrochloride 

Downstream Products

• 1442452-06-3 5-chloro-6-(4-fluoro-benzyloxy)-2-methyl-3-(2-methyl-5-propynoyl-phenyl)-3H-pyrimidin-4-one 
• 1442451-77-5 5-chloro-6-((4-fluorobenzyl)oxy)-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-2-methylphenyl)-2-methylpyrimidin-4(3H)-one 

Relevant articles and documents

SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS

The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.